Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada

At the current marketed price, first-line osimertinib therapy in patients with advanced EGFR-mutant lung adenocarcinoma is not cost-effective in Canada. Reduction of osimertinib cost, for example by 25%, can significantly improve the cost-effectiveness profile.